A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Summary

This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia

Eligibility

Inclusion Criteria:

* Voluntary written informed consent and willingness to comply with all study procedures
* Age ≥ 18 years
* Confirmed diagnosis of acute myeloid leukemia (AML)
* Patients with R/R AML with NPM1-m
* No available standard of care expected to provide clinical benefit, ineligible for or declined standard therapy.
* ECOG performance status 0-2.
* White blood cell count ≤ 30,000/mm³ at screening (hydroxyurea permitted for cytoreduction).
* Adequate organ function according to protocol requirements.
* Women of childbearing potential must be willing to use a highly effective method of contraception throughout the study and for at least 187 days after the last dose of study treatment.
* Males with female partners of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 97 days after the last dose of study treatment.

Exclusion Criteria:

* Diagnosis of acute promyelocytic leukemia.
* Donor lymphocyte infusion \< 30 days prior to study entry.
* Clinically active central nervous system (CNS) leukemia.
* Prior hematopoietic stem cell transplantation (HSCT) without adequate hematologic recovery.
* Active Grade ≥ 2 acute graft-versus-host disease or moderate/severe chronic graft-versus-host disease.
* Prior treatment with a menin inhibitor.
* Receipt of chemotherapy, immunotherapy, radiotherapy, or investigational therapy within 14 days or 5 half-lives prior to first dose.
* Unresolved toxicities from prior therapy \> Grade 1.
* Requirement for strong CYP3A4 inducers.
* Active or uncontrolled infection, including hepatitis B, hepatitis C, or HIV.
* Conditions predisposing to serious or life-threatening infection or significant immunodeficiency.
* Cardiovascular disease or QTcF \> 480 ms.
* Interstitial lung disease.
* Major surgery within 4 weeks prior to first dose.
* Women who are pregnant or lactating
* Any medical, psychiatric, or social condition that may interfere with study participation or safety, or that makes the patient unsuitable in the investigator's judgment.

Conditions2

Interventions1

Related trials

• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — Kura Oncology, Inc.
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Kura Oncology, Inc.
• Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML — Kura Oncology, Inc.
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — Kura Oncology, Inc.
• TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II — Tanja Andrea Gruber
• Ziftomenib Maintenance Post Allo-HCT — Massachusetts General Hospital
• A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia — M.D. Anderson Cancer Center
• Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia — M.D. Anderson Cancer Center

Browse More Trials